Arrowhead initiated with a Neutral at Goldman Sachs

Goldman Sachs analyst Andrea Tan initiated coverage of Arrowhead Pharmaceuticals with a Neutral rating and $31 price target. Arrowhead is a near-commercial stage company leveraging its proprietary TRiM platform to develop RNAi therapies across various disease indications, the analyst tells investors in a research note. The firm sees the company’s key value drivers as emerging likely in 202 and beyond, starting with plozasiran SHASTA registrational studies and the Phase 2b ARO-RAGE data in asthma.